Sunmax Biotechnology Co., Ltd.

Total Valuation

Sunmax Biotechnology Co., Ltd. carries a market capitalization of 20.64B, placing it among publicly traded companies globally. Its enterprise value stands at 20.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Sunmax Biotechnology Co., Ltd. currently has 54.46M shares outstanding.

Valuation Ratios

Sunmax Biotechnology Co., Ltd. trades at a trailing price-to-earnings ratio of 29.74. The price-to-sales ratio is 10.65, and the price-to-book ratio stands at 16.04.

Enterprise Valuation

On an enterprise value basis, Sunmax Biotechnology Co., Ltd. trades at an EV/EBITDA multiple of 20.78 and an EV/FCF ratio of 23.10. The EV/Sales ratio of 10.24 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.78 provides insight into valuation relative to core operating earnings.

Financial Position

Sunmax Biotechnology Co., Ltd. maintains a current ratio of 3.89, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.38, indicating elevated leverage, while an interest coverage ratio of 204.40 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Sunmax Biotechnology Co., Ltd. posts a return on equity of 54.61 and a return on invested capital of 40.29.

Taxes

Over the trailing twelve months, Sunmax Biotechnology Co., Ltd. has paid 288.83M in income taxes, reflecting an effective tax rate of 28.47.

Stock Price Statistics

Sunmax Biotechnology Co., Ltd.'s stock has declined approximately -4.41362% over the past 52 weeks. The 50-day moving average sits at 387.11, while the 200-day moving average is 394.52.

Income Statement

Over the trailing twelve months, Sunmax Biotechnology Co., Ltd. generated 2.03B in revenue and converted that into 725.75M in net income, yielding earnings per share of 13.31. EBITDA reached 998.31M, while operating income came in at 998.31M.

Balance Sheet

Sunmax Biotechnology Co., Ltd. holds 961.59M in cash and equivalents against 119.33M in total debt, resulting in a net debt position of -711.59M. Total book value stands at 1.35B, with working capital of 849.33M providing operational flexibility.

Cash Flow

Sunmax Biotechnology Co., Ltd. produced 825.92M in operating cash flow over the past twelve months. After subtracting -68.33M in capital expenditures, free cash flow totaled 757.58M - equivalent to 13.90 per share.

Margins

Sunmax Biotechnology Co., Ltd. operates with a gross margin of 78.41, reflecting its pricing power and cost economics. The operating margin of 49.27 and net profit margin of 35.82 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Sunmax Biotechnology Co., Ltd.'s most recent stock split took place on May 7, 2010 with a 500:541 split ratio.

Scores

Sunmax Biotechnology Co., Ltd. posts an Altman Z-Score of 29.14, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.